@oneortwo1234 Avatar @oneortwo1234 oneortwo1234

oneortwo1234 posts on X about $ocul, $apls, up to, wet the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: [--] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [--] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 8% technology brands 8%

Social topic influence $ocul #55, $apls 28%, up to 8%, wet 4%, execution 4%, timeline 4%, company 4%, more than 4%, upside 4%, strong 4%

Top accounts mentioned or mentioned by @statnews @zipjet @tomsilver39 @retinatoday @paperboy2009 @george_deng7

Top assets mentioned Ocular Therapeutix, Inc. (OCUL) Apellis Pharmaceuticals, Inc. Common Stock (APLS)

Top Social Posts

Top posts by engagements in the last [--] hours

"$ocul Ocular Therapeutix faces looming test of a more durable eye treatment via @statnews https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/ https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/"
X Link 2026-01-08T13:09Z [--] followers, [---] engagements

"$ocul Ocular Therapeutix is nearing a pivotal wet AMD readout for its Axpaxli which is administered less frequently at six months between doses. Vabysmo allows for treatment intervals of up to four months. https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study"
X Link 2026-01-30T03:43Z [--] followers, [----] engagements

"$ocul Robinson:"My experience leading the launch of EYLEA showed me firsthand how meaningful innovation coupled with disciplined execution can reshape treatment paradigms and create entirely new standards of care. I see similar potential with https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/ https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/"
X Link 2026-02-03T19:20Z [--] followers, [----] engagements

"$ocul The Company further intends to leverage the 505(b)(2)approval pathway which could potentially shorten the NDA review timeline for AXPAXLI by up to two months. https://investors.ocutx.com/node/14586/html https://investors.ocutx.com/node/14586/html"
X Link 2026-02-05T13:04Z [--] followers, [---] engagements

"$ocul RBC projects potential upside of more than 100% for OCUL https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-outperform-rating-on-ocular-therapeutix-stock-93CH-4491011 https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-outperform-rating-on-ocular-therapeutix-stock-93CH-4491011"
X Link 2026-02-06T17:19Z [--] followers, [---] engagements

"$apls" We believed that you know this could be related to the needle which they changed it. And since then we have not seen any side effects due to Syfovre. And I have been using both complement inhibitors very confidently and I have not seen any side effects in my patients.""
X Link 2025-11-15T20:07Z [--] followers, [--] engagements

"$apls https://press.spglobal.com/index.phps=2429&item=136445 https://press.spglobal.com/index.phps=2429&item=136445"
X Link 2026-01-28T02:20Z [--] followers, [--] engagements

"$ocul Looks like there's an update on Helios DR in addition to SOL-1 (Phase [--] wet AMD) superiority trial at the Macula Society. https://www.xcdsystem.com/maculasociety/program/IUDYmFD/index.cfmpgid=416 https://www.xcdsystem.com/maculasociety/program/IUDYmFD/index.cfmpgid=416"
X Link 2026-02-05T17:10Z [--] followers, [---] engagements

"@zipjet $ocul All this hoopla has increased the odds of the data being unveiled in the Feb 16-20 timeframe"
X Link 2026-02-05T19:43Z [--] followers, [---] engagements

"@tomsilver39 $ocul BoA must have strong conviction about the impending data it's remarkable that they not only mention Ocul as one of their top Buys they raise the PO"
X Link 2026-02-06T02:29Z [--] followers, [---] engagements

"$ocul https://www.stocktitan.net/sec-filings/OCUL/schedule-13g-a-ocular-therapeutix-inc-amended-passive-investment-disc-25d1f76d2f7d.html https://www.stocktitan.net/sec-filings/OCUL/schedule-13g-a-ocular-therapeutix-inc-amended-passive-investment-disc-25d1f76d2f7d.html"
X Link 2026-02-10T16:06Z [--] followers, [---] engagements

"5.13% stake per latest disclosure http://archive.fast-edgar.com/20260210/AT22M22CZ22CSJK222222ZO2TUJHIZ223282/ http://archive.fast-edgar.com/20260210/AT22M22CZ22CSJK222222ZO2TUJHIZ223282/"
X Link 2026-02-10T22:03Z [--] followers, [--] engagements

"$ocul Ocular Therapeutix Strategy & AXPAXLI Outlook https://www.hdinresearch.com/news/835#::text=*%20AXPAXLI%20(OTX%2DTKI)%20Market%20Potential%3Adata%20suggests%20a%206%2D9%20month https://www.hdinresearch.com/news/835#::text=*%20AXPAXLI%20(OTX%2DTKI)%20Market%20Potential%3Adata%20suggests%20a%206%2D9%20month"
X Link 2026-02-13T15:03Z [--] followers, [---] engagements

"$ocul Fidelity reports a 15% stake https://archive.fast-edgar.com/20251105/AQLZE622C222AZZ2222B2ZZZK4SNZ232PW72/ https://archive.fast-edgar.com/20251105/AQLZE622C222AZZ2222B2ZZZK4SNZ232PW72/"
X Link 2025-11-05T16:50Z [--] followers, [--] engagements

"@RetinaToday $apls"
X Link 2026-01-12T18:15Z [--] followers, [--] engagements

"$ocul [--] Clinical Readouts to Watch in H1 [----] https://www.biospace.com/drug-development/5-clinical-readouts-to-watch-in-h1-2026 https://www.biospace.com/drug-development/5-clinical-readouts-to-watch-in-h1-2026"
X Link 2026-01-05T13:40Z [--] followers, [---] engagements

"$ocul Could the weakness be because a fund is exiting their position Hope that the selling pressure abates and Ocul can rally"
X Link 2026-01-30T20:25Z [--] followers, [---] engagements

"$apls "we have not seen any side effects due to Syfovre." This interview is huge We all know that Syfovre is more effective than Izervay but there was always a cloud surrounding potential side effects. This interview puts that notion to rest. https://europe.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents https://europe.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents"
X Link 2025-11-15T19:29Z [--] followers, [--] engagements

"$apls "since October [----] the last case of retinal vasculitis which was reported due to Syfovre that was the last case. And after that there have been no events.""
X Link 2025-11-15T20:07Z [--] followers, [--] engagements

"$ocul What to keep an eye on in [----] https://glance.eyesoneyecare.com/stories/2026-01-02/what-to-keep-an-eye-on-in-2026/ https://glance.eyesoneyecare.com/stories/2026-01-02/what-to-keep-an-eye-on-in-2026/"
X Link 2026-01-02T20:24Z [--] followers, [---] engagements

"$apls Apellis added to S&P 600"
X Link 2026-01-28T02:21Z [--] followers, [--] engagements

"$apls https://www.insidermonkey.com/blog/11-best-high-short-interest-stocks-with-biggest-upside-potential-1681595/ https://www.insidermonkey.com/blog/11-best-high-short-interest-stocks-with-biggest-upside-potential-1681595/"
X Link 2026-01-28T13:51Z [--] followers, [--] engagements

"$ocul On December [--] [----] Ocular Therapeutix announced it will enter a quiet period starting December [--] [----] as it prepares for database lock of its SOL-1 Phase [--] clinical trial of AXPAXLI https://www.theglobeandmail.com/investing/markets/stocks/OCUL-Q/pressreleases/36722510/ocular-therapeutix-enters-quiet-period-ahead-of-sol-1-milestone/ https://www.theglobeandmail.com/investing/markets/stocks/OCUL-Q/pressreleases/36722510/ocular-therapeutix-enters-quiet-period-ahead-of-sol-1-milestone/"
X Link 2025-12-24T16:31Z [--] followers, [---] engagements

"$ocul https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/ https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/"
X Link 2025-12-31T16:49Z [--] followers, [---] engagements

"https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/ https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/"
X Link 2025-12-31T16:52Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing